Pharma Mar, S.A.
Pharma Mar, S.A. Fundamental Analysis
Pharma Mar, S.A. (PHMMF) shows moderate financial fundamentals with a PE ratio of 38.40, profit margin of 19.02%, and ROE of 16.94%. The company generates $0.2B in annual revenue with strong year-over-year growth of 10.56%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 70.6/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze PHMMF's fundamental strength across five key dimensions:
Efficiency Score
WeakPHMMF struggles to generate sufficient returns from assets.
Valuation Score
ModeratePHMMF shows balanced valuation metrics.
Growth Score
ExcellentPHMMF delivers strong and consistent growth momentum.
Financial Health Score
ExcellentPHMMF maintains a strong and stable balance sheet.
Profitability Score
ExcellentPHMMF achieves industry-leading margins.
Key Financial Metrics
Is PHMMF Expensive or Cheap?
P/E Ratio
PHMMF trades at 38.40 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, PHMMF's PEG of -2.37 indicates potential undervaluation.
Price to Book
The market values Pharma Mar, S.A. at 6.62 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 33.77 times EBITDA. This signals the market has high growth expectations.
How Well Does PHMMF Make Money?
Net Profit Margin
For every $100 in sales, Pharma Mar, S.A. keeps $19.02 as profit after all expenses.
Operating Margin
Core operations generate 11.03 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $16.94 in profit for every $100 of shareholder equity.
ROA
Pharma Mar, S.A. generates $9.96 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Pharma Mar, S.A. produces operating cash flow of $21.00M, showing steady but balanced cash generation.
Free Cash Flow
Pharma Mar, S.A. produces free cash flow of $16.05M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.93 in free cash annually.
FCF Yield
PHMMF converts 1.26% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
38.40
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-2.37
vs 25 benchmark
P/B Ratio
Price to book value ratio
6.62
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.21
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.25
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.73
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.17
vs 25 benchmark
ROA
Return on assets percentage
0.10
vs 25 benchmark
ROCE
Return on capital employed
0.08
vs 25 benchmark
How PHMMF Stacks Against Its Sector Peers
| Metric | PHMMF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 38.40 | 29.45 | Worse (Expensive) |
| ROE | 16.94% | 779.00% | Weak |
| Net Margin | 19.02% | -24936.00% (disorted) | Strong |
| Debt/Equity | 0.25 | 0.26 | Neutral |
| Current Ratio | 2.73 | 4.65 | Strong Liquidity |
| ROA | 9.96% | -19344.00% (disorted) | Weak |
PHMMF outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Pharma Mar, S.A.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
114.18%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
399.16%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
124.24%
Industry Style: Defensive, Growth, Innovation
High Growth